Search results
Found 685 matches for
Welcome From Prof Wood
The laboratory works at the interface of neuromuscular science and biotechnology. A major focus is the study of neuromuscular diseases such as Duchenne muscular dystrophy, myotonic dystrophy and spinal muscular atrophy and the development of gene-based therapies, in particular RNA-based therapies, for this class of disorders. A central challenge in our work is the effective delivery of such therapies to the target tissues of skeletal muscle, heart and nervous system. To address this the team has pioneered the development of numerous delivery technologies ranging from peptide to antibody to nanotechnologies based on natural nanoparticles known as exosomes. Our goal is to advance the science underlying these innovative therapies to develop the truly innovative precision medicines of the future and to advance their translation to the benefit of patients. Please join our efforts! Professor Matthew Wood
Oxford Harrington Rare Disease Centre
The University of Oxford and University Hospitals in Cleveland, Ohio, have announced a multi-year affiliation to establish a global centre for rare diseases.
Our Research
We work at the interface of biotechnology and biomedicine. Our major focus is on RNA biology and RNA therapeutics as applied primarily to rare neuromuscular diseases.
EV biology and therapeutics
Extracellular vesicles are heterogeneous intercellular communicators and a bioengineering platform for the delivery of biotherapeutics.
Neuromuscular Diseases
The Wood lab is a leading research group focused on rare neuromuscular disease biology and the development of novel therapies for neuromuscular disorders including Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA) and more recently myotonic dystrophy type 1 (DM1).
Matthew Wood's Short Bio
Matthew Wood is Professor of Neuroscience at the University of Oxford and Deputy Head of the University of Oxford Medical Sciences Division. He is currently director of the MDUK Oxford Neuromuscular Centre and director of the Oxford Harrington Rare Disease Centre. The laboratory has many collaborations with industry including with two recent spin-out companies from the Wood Lab – Evox Therapeutics and PepGen